Yes, maybe. But the COPIKTRA launch doesn't get enough traction and IMO probably has failed. PTCL and other combo trials might be too far away - with 40m per quarter burn, this will kill them in about 2 years or at least cause massive dilution. I am only holding because there is at least one Phase 2 readout from their other candidate, defactinib, in solid tumours. Low chance of success, but if one readout is successful, it might cause a massive squeeze.

Did you see the strong reversal in CRMD? Would be good if it gets back over the 50 and 200 MA.